Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NTRB
stocks logo

NTRB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
765.00K
+19.09%
-2.130
+1675%
Estimates Revision
The market is revising No Change the revenue expectations for Nutriband Inc. (NTRB) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -20.69%.
Revenue Estimates for FY2026
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2026
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-20.69%
In Past 3 Month
Wall Street analysts forecast NTRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRB is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast NTRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRB is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.060
sliders
Low
15.00
Averages
15.00
High
15.00
Current: 5.060
sliders
Low
15.00
Averages
15.00
High
15.00
Noble Capital Markets
Robert LeBoyer
Buy
Initiates
$13
2025-01-22
Reason
Noble Capital Markets
Robert LeBoyer
Price Target
$13
2025-01-22
Initiates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Nutriband Inc (NTRB.O) is 10.02, compared to its 5-year average forward P/E of -2.99. For a more detailed relative valuation and DCF analysis to assess Nutriband Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.99
Current PE
10.02
Overvalued PE
113.84
Undervalued PE
-119.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.15
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
60.75
Undervalued EV/EBITDA
-61.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
16.49
Current PS
0.00
Overvalued PS
38.37
Undervalued PS
-5.39
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

NTRB News & Events

Events Timeline

(ET)
2025-10-28
07:13:46
Nutriband Reports Successful Meeting with U.S. FDA Regarding AVERSA FENTANYL
select
2025-10-27 (ET)
2025-10-27
07:07:15
Gareth Sheridan Reassumes Role as CEO of Nutriband
select
2025-10-10 (ET)
2025-10-10
07:02:57
Nutriband partners with Brand Institute to create branding for patch product.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-13NASDAQ.COM
Korro Bio, Inc. (KRRO) Announces Q3 Loss and Falls Short of Revenue Projections

  • Quarterly Performance: Korro Bio, Inc. reported a quarterly loss of $1.92 per share, better than the Zacks Consensus Estimate of a loss of $2.61, marking a 26.44% earnings surprise. The company also generated $1.09 million in revenue, missing estimates by 27.33%.

  • Stock Outlook: Despite underperforming the market with a 13.8% decline since the start of the year, Korro Bio holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market. Future stock movements will depend on earnings estimate revisions and management's commentary.

  • Industry Context: The Medical - Drugs industry, to which Korro Bio belongs, is currently ranked in the top 32% of Zacks industries, suggesting a favorable environment for stocks in this sector.

  • Comparative Analysis: Nutriband Inc., another company in the same industry, is expected to report a significant quarterly loss, with its revenue forecast showing a slight increase. Investors are encouraged to consider broader industry trends when evaluating Korro Bio's performance.

[object Object]
Preview
9.5
11-12NASDAQ.COM
Metagenomi (MGX) Posts Q3 Loss, Falls Short of Revenue Projections

  • Quarterly Performance: Metagenomi reported a quarterly loss of $0.55 per share, slightly better than the expected loss of $0.60, but worse than a loss of $0.45 per share a year ago. The company also posted revenues of $8.66 million, missing estimates by 6.44%.

  • Stock Performance: Metagenomi shares have declined by approximately 40.4% since the start of the year, contrasting with a 16.2% gain in the S&P 500. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.

  • Earnings Outlook: The consensus EPS estimate for the upcoming quarter is -$0.50 on revenues of $9.26 million, while the fiscal year estimate is -$2.39 on $30.44 million in revenues. The mixed trend in earnings estimate revisions could influence future stock performance.

  • Industry Context: The Medical - Drugs industry, to which Metagenomi belongs, is currently ranked in the top 33% of Zacks industries, suggesting a favorable environment for stocks in this sector. Another company in the same industry, Nutriband Inc., is expected to report a significant loss in its upcoming results.

[object Object]
Preview
5.0
10-27NASDAQ.COM
Nutriband Co-Founder Gareth Sheridan Reassumes Position as CEO

  • Leadership Change: Nutriband, Inc. announced that Gareth Sheridan has returned as CEO after a three-month hiatus to participate in the Irish Presidential election.

  • Interim Leadership: During Sheridan's absence, Co-Founder and Chairman Serguei Melnik served as the acting CEO from August 10 to October 27.

  • Future Plans: Sheridan will lead the company towards the NDA filing for AVERSA Fentanyl, targeting completion in 2026.

  • Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Nutriband Inc (NTRB) stock price today?

The current price of NTRB is 5.06 USD — it has increased 10.96 % in the last trading day.

arrow icon

What is Nutriband Inc (NTRB)'s business?

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

arrow icon

What is the price predicton of NTRB Stock?

Wall Street analysts forecast NTRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRB is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Nutriband Inc (NTRB)'s revenue for the last quarter?

Nutriband Inc revenue for the last quarter amounts to 622.45K USD, increased 40.56 % YoY.

arrow icon

What is Nutriband Inc (NTRB)'s earnings per share (EPS) for the last quarter?

Nutriband Inc. EPS for the last quarter amounts to -2.12 USD, increased 1313.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Nutriband Inc (NTRB)'s fundamentals?

The market is revising No Change the revenue expectations for Nutriband Inc. (NTRB) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -20.69%.
arrow icon

How many employees does Nutriband Inc (NTRB). have?

Nutriband Inc (NTRB) has 3 emplpoyees as of December 05 2025.

arrow icon

What is Nutriband Inc (NTRB) market cap?

Today NTRB has the market capitalization of 60.66M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free